Business
Protara Therapeutics Announces Updated Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients
TARA-002 demonstrates 72% complete response rate at any time in BCG-Naïve patientsTARA-002 demonstrates a 69% complete response rate at the 6-month landmark and a 50% complete response rate at the 12-month landmark in BCG-Naïve patientsFavorable safety and tolerability profile observed with no Grade 3 or greater treatment-related adverse events reportedCompany obtained written feedback from FDA on registrational path forward for TARA-002 in BCG-Naïve patientsCompany remains on track to report in
About this update from Protara Therapeutics, Inc.
[{"type":"image","alt":"Protara Therapeutics","displaySize":"","headline":null,"caption":"Protara Therapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":106,"url":"https://media.zenfs.com/en/globenewswire.com/859264115c175ddb8556462fe6954a72"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/UG_sFiObOKNigh1f.P_1zg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0ODtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/859264115c175ddb8556462fe6954a72","width":300,"height":106}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"TARA-002 demonstrates 72% complete response rate at any time in BCG-Naïve patients","length":82,"tagName":"p"}]},{"val":[{"type":"text","content":"TARA-002 demonstrates a 69% complete response rate at the 6-month landmark and a 50% complete response rate at the 12-month landmark in BCG-Naïve patients","length":154,"tagName":"p"}]},{"val":[{"type":"text","content":"Favorable safety and tolerability profile observed with no Grade 3 or greater treatment-related adverse events reported","length":119,"tagName":"p"}]},{"val":[{"type":"text","content":"Company obtained written feedback from FDA on registrational path forward for TARA-002 in BCG-Naïve patients","length":108,"tagName":"p"}]},{"val":[{"type":"text","content":"Company remains on track to report interim results from approximately 25 six-month evaluable BCG-Unresponsive patients in the registrational cohort of the ADVANCED-2 trial in Q1 2026 ","length":182,"tagName":"p"}]},{"val":[{"type":"text","content":"Company expects to complete enrollment of the BCG-Unresponsive registrational cohort of the ADVANCED-2 trial in 2H 2026","length":119,"tagName":"p"}]},{"val":[{"type":"text","content":"Company to host conference call and webcast today at 8:30 a.m. ET","length":65,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":829,"olType":false},{"type":"text","content":"NEW YORK, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced updated interim data from the ongoing Phase 2 open-label ADVANCED-2 trial of TARA-002 in patients with carcinoma in situ or CIS (± Ta/T1) non-muscle invasive bladder cancer (NMIBC). These results in Bacillus Calmette-Guérin (BCG)-Naïve NMIBC patien...